


Bridging the Cloning Throughput Gap in Antibody Therapeutics Discovery


There is increased pressure on antibody discovery pipelines to identify and validate high-quality lead candidates to meet the demand for new therapeutics against difficult target classes such as GPCRs and ion channels.



Current FDA Approved Drug Targets

Antib Ther. 2020 Dec 9;3(4):257-264.


While there is significant therapeutic potential in these targets, identification of functional antibodies has been limited due to challenges in the discovery process. In fact, difficult targets and discovery processes were the top listed challenges in a recent state of the industry report.



Top Challenges in Antibody Development

Adapted from Antibody Engineering and Therapeutics State of the Industry Report 2021


Difficult target classes require screening of large pools of candidate antibodies, but cloning workflows impose a throughput bottleneck



Automating Synthetic Biology Overcomes the Cloning Bottleneck by Rapidly Connecting High-content Sequencing Data to Downstream Characterization

Traditional Manual Workflow

4-5 weeks to complete gene synthesis and plasmid assembly



Automated BioXp Workstation

Build and amplify 24 plasmids per day



Accelerate Antibody Discovery With Telesis Bio



Learn More About Process Optimization
in Antibody Discovery

DOWNLOAD THE WHITE PAPER



telesisbio.com/process-optimization-in-antibody-discovery-workflows